Scarica l'app Stockscreener
10.55
2.68%
-0.29
Dopo l'orario di chiusura:
10.51
-0.04
-0.38%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NVCR Giù?
Forum
Previsione
Novocure Ltd Borsa (NVCR) Ultime notizie
NovoCure (NVCR) Jumps After Strong PANOVA-4 Data Validates TTFields Combo Potential In Pancreatic Cancer - Sahm
JPMorgan Chase & Co. Buys 144,024 Shares of NovoCure Limited $NVCR - MarketBeat
NovoCure Ltd (038.DU) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
NovoCure Limited (NVCR) stock price, news, quote and history - Yahoo Finance UK
SG Americas Securities LLC Boosts Position in NovoCure Limited $NVCR - marketbeat.com
NovoCure Tumor Treating Fields Shows Improved Outcomes In Tough Pancreatic Cancer - MSN
NovoCure (NVCR) Is Down 6.6% After Strong PANOVA-4 Phase 2 Data In Metastatic Pancreatic Cancer – Has The Bull Case Changed? - Yahoo Finance
NovoCure Ltd to release first quarter 2026 financial results on April 30 - Traders Union
Novocure to Report First Quarter 2026 Financial Results - Yahoo Finance
NovoCure Limited (NASDAQ:NVCR) Given Average Recommendation of "Hold" by Brokerages - marketbeat.com
NovoCure’s EF-32 Optune® Trial Reaches Completion, Setting Up a Key Catalyst for NVCR Investors - TipRanks
A Look At NovoCure (NVCR) Valuation After Extended Share Price Weakness - simplywall.st
H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $49 - Moomoo
NovoCure Ltd (NVCR) Stock Price, Quote, News & History - Benzinga
NovoCure Limited Files 8-K Report Detailing Tumor Treating Fields Therapy and Corporate Information March 2026 - Minichart
Vanguard disaggregates ownership reporting for Novocure (NVCR) after realignment - stocktitan.net
NVCR SEC FilingsNovocure 10-K, 10-Q, 8-K Forms - Stock Titan
Does Positive PANOVA-4 Data Alter the Bull Case For NovoCure’s TTFields Platform (NVCR)? - simplywall.st
Brain Cancer Market Growth in Future Scope 2026-2033 | Novocure, - openpr.com
Novocure (NVCR) Reports Positive Phase 2 Results for TTFields Th - GuruFocus
Novocure (NVCR) Achieves Key Milestone in Pancreatic Cancer Tria - GuruFocus
Novocure reports positive Phase 2 trial results for pancreatic cancer By Investing.com - Investing.com India
Novocure stock rises on positive pancreatic cancer trial data By Investing.com - Investing.com Australia
PANOVA-4 Phase 2 trial shows promising TTFields therapy results, NovoCure Ltd reveals - Traders Union
Novocure (NASDAQ: NVCR) reports positive PANOVA-4 pancreatic cancer data - Stock Titan
Pancreatic cancer trial posts 74.4% disease control with Novocure - Stock Titan
Is NovoCure (NVCR) Now Pricing In Too Much Pessimism After Prolonged Share Price Slump - Yahoo Finance
Tudor Investment Corp ET AL Purchases 354,216 Shares of NovoCure Limited $NVCR - MarketBeat
NovoCure Limited $NVCR Position Lifted by Algert Global LLC - MarketBeat
Capital World Investors Lowers Holdings in NovoCure Limited $NVCR - MarketBeat
FDA Approves Novocure’s Optune Pax Wearable Device for Pancreatic Cancer - Digital Health News
NovoCure Limited $NVCR Shares Acquired by American Century Companies Inc. - MarketBeat
Novocure at Leerink Conference: Strategic Growth in Cancer Treatment By Investing.com - Investing.com South Africa
Novocure at Leerink Conference: Strategic Growth in Cancer Treatment - Investing.com Australia
Should Japan’s Optune Lua Reimbursement Win Reframe NovoCure’s (NVCR) Access and Utilization Story? - Sahm
Novocure's Optune Lua Gets Japan Reimbursement for NSCLC Treatment - Yahoo Finance
Assessing Novocure (NVCR) Valuation After Japan Reimbursement Approval For Optune Lua - Sahm
NovoCure Limited (NASDAQ:NVCR) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Insider Selling: NovoCure (NASDAQ:NVCR) Insider Sells 1,100 Shares of Stock - MarketBeat
NovoCure (NASDAQ:NVCR) CFO Sells $85,343.72 in Stock - MarketBeat
NovoCure (NASDAQ:NVCR) CEO Sells $74,629.17 in Stock - MarketBeat
Mukund Paravasthu Sells 5,377 Shares of NovoCure (NASDAQ:NVCR) Stock - MarketBeat
NovoCure (NASDAQ:NVCR) COO Mukund Paravasthu Sells 43,246 Shares - MarketBeat
NVCR Crosses Above Key Moving Average Level - Nasdaq
Tax-driven sale: NovoCure (NVCR) ex-CMO offloads 1,100 shares to cover RSU taxes - Stock Titan
NovoCure (NVCR) General Counsel receives new stock options and RSU grants - Stock Titan
NovoCure (NASDAQ: NVCR) CMO reports tax sale and new stock awards - Stock Titan
Mukund Paravasthu sells Common shares via Morgan Stanley (NVCR) - Stock Titan
[144] NovoCure Ltd SEC Filing - Stock Titan
NVCR (NASDAQ) Form 144: Insider-related sales include 3,272 and 7,461 shares - Stock Titan
NovoCure Ltd. Hits Day Low of $11.80 Amid Price Pressure - Markets Mojo
Vanguard Group Inc. Sells 296,555 Shares of NovoCure Limited $NVCR - MarketBeat
NovoCure Limited $NVCR Shares Bought by Quantbot Technologies LP - MarketBeat
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):